Work

A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.10003

Authors: Michael A. Postow, Debra A Goldman, Alexander Noor Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Ellesa Naito, Omar Eton, Suresh Nair, Jedd D. Wolchok, Katherine Panageas, Paul B. Chapman

Institutions: Memorial Sloan Kettering Cancer Center, Boston University, Lehigh Valley Health Network

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3028638056

Cites:

Cited by: 19

Related to: 10